cs.LGSep 16, 2026

Interpretable Multi-Instance Learning Enables Early Prediction of Key Molecular Alterations from Routine Flow Cytometry in Acute Myeloid Leukemia

Authors: Jonathan Legrand, Aguirre Mimoun, Baudouin Denis de Senneville, Audrey Bidet, Pierre-Yves Dumas, Christèle Etchegaray

Organizations: IMB, MONC · CHU Bordeaux · CHU Bordeaux, Inserm U1312 - BRIC · MONC, IMB

Abstract

Background: Molecular testing for NPM1 and FLT3-ITD mutations guides critical early treatment decisions in acute myeloid leukemia (AML), but results can take weeks, long after these decisions must be made. Flow cytometry, already performed within hours of admission as part of routine care, may carry enough signal to predict these mutations directly, without added cost or delay. Methods: We developed an interpretable multi-instance learning classifier based on a decision tree, in which each patient sample is modeled as a collection of individual cells and mutation status is inferred from cell-level predictions. The model was benchmarked against a random forest trained on clinical variables and a deep convolutional neural network adapted for multitube flow cytometry data. Performance was assessed by cross-validation on a discovery cohort of 197 patients and tested on an independent cohort of 161 patients, using the area under the receiver operating characteristic curve (AUROC) and positive predictive value. Results: In cross-validation on the discovery cohort, the MIL model achieved mean AUROCs of 0.96 (SD=0.05) for NPM1 and 0.86 (SD=0.10) for FLT3-ITD, outperforming the clinical baseline and matching deep learning approaches. The model then successfully generalized to the independent test cohort of 161 patients, reaching AUROCs of 0.90 (NPM1) and 0.82 (FLT3-ITD), with positive predictive values of 0.87 and 0.68, respectively. Cell-level interpretation recovered established immunophenotypic signatures (CD33+{}^{+} /CD34___ for NPM1-mutated cases, CD33+{}^{+} /low side-scatter for FLT3-ITD), directly linking model predictions to known biology. Conclusions: These results show that an interpretable model applied to data already collected in routine care can predict AML molecular status within hours, offering a practical route to earlier, biology-informed treatment decisions.

Explore similar work

CardsList
Jun 9, 2026cs.CV

Patient-Level Diagnosis of Acute Myeloid Leukemia via Deep Learning Analysis of Bone Marrow Smear

Bone marrow smear review remains important for acute myeloid leukemia (AML) assessment, but manual single-cell interpretation is labor-intensive and patient-level diagnosis requires aggregation of many cellular observations. We present a cell-to-patient deep learning pipeline for AML-assisted diagnosis from bone marrow smear images. The study included 258 patients from six anonymized centers, including a main cohort of 169 patients from Centers 1-3 and an external validation cohort of 89 patients from Centers 4-6. A 16-category cell annotation vocabulary was used to describe the global cellular composition, including granulocytic, monocytic, erythroid, lymphoid, eosinophilic, and other cells. Rather than identifying strict AML blasts or leukemic blasts, the model targets an expert-defined composite category termed Composite Blast-like Cells (CBLC), comprising N, N1, M, M1, R, R1, J, and J1 according to the project-wide morphological standard. A fixed YOLO-based segmentation module detected cells, predicted contours were matched to expert polygon annotations by contour IoU, and standardized single-cell crops were generated. An EfficientNet-B0 classifier was trained through a two-stage GT-to-YOLO and YOLO-to-YOLO strategy with class-imbalance correction, center-border regularization, and morphology-assisted supervision. Cell-level predictions were aggregated into patient-level CBLC ratios for AML-oriented diagnostic support. The pipeline achieved stable internal validation and maintained external generalization, with ensemble weighted F1-scores of 0.9076, 0.8696, and 0.9124 on Centers 4, 5, and 6, respectively.
Yuqi Ma, Tianyi Wang, Weihua Meng +6
Acute Myeloid LeukemiaSingle-Cell Rna Sequencing
AskPDF
Apr 17, 2026cs.CV

Early Detection of Acute Myeloid Leukemia (AML) Using YOLOv12 Deep Learning Model

Acute Myeloid Leukemia (AML) is one of the most life-threatening type of blood cancers, and its accurate classification is considered and remains a challenging task due to the visual similarity between various cell types. This study addresses the classification of the multiclasses of AML cells Utilizing YOLOv12 deep learning model. We applied two segmentation approaches based on cell and nucleus features, using Hue channel and Otsu thresholding techniques to preprocess the images prior to classification. Our experiments demonstrate that YOLOv12 with Otsu thresholding on cell-based segmentation achieved the highest level of validation and test accuracy, both reaching 99.3%.
Enas E. Ahmed, Salah A. Aly, Mayar Moner
Acute Myeloid LeukemiaDeep LearningMultilevel Image Thresholding
AskPDF
Jun 23, 2026eess.IV

A Leakage-Aware Comparative Benchmark of Machine Learning, Deep Learning, and Transformer Models for Reliable Leukemia Detection

Automated classification of acute lymphoblastic leukemia (ALL) from peripheral blood smear images has often reported near-perfect performance on the C-NMC 2019 dataset. We show that such results can be inflated by patient-level data leakage caused by random image-level partitioning, where cells from the same subject may appear in both training and test folds. We establish a leakage-aware benchmark under a strict subject-disjoint protocol, comparing LightGBM, RBF-SVM, EfficientNet-B0, EfficientNet-B1, and ViT-Tiny. Models are developed using three subject-disjoint folds from 73 subjects and evaluated on an external preliminary-phase test set of 1,867 images from 28 unseen subjects with zero patient overlap. Beyond discrimination, we assess calibration using expected calibration error, Brier score, and temperature scaling. Under honest evaluation, EfficientNet-B1 achieves the best performance, with AUROC 0.913, sensitivity 0.87, specificity 0.80, and calibrated ECE 0.024. Frozen-feature classifiers and ViT-Tiny show high sensitivity but poor specificity, indicating a tendency to over-predict the malignant class. A random-versus-subject-disjoint ablation shows that random splitting inflates AUROC by about 0.04 even in the conservative frozen-feature setting. These findings caution against image-level evaluation on C-NMC 2019 and provide a reproducible, calibration-aware benchmark for future work.
Nisreen Albzour
Acute Myeloid LeukemiaAuc-RocMachine LearningDeep LearningAblation
AskPDF